ADCS-ADL

AcronymDefinition
ADCS-ADLAlzheimer's Disease Cooperative Study - Activities of Daily Living
References in periodicals archive ?
Higher scores on the ADCS-ADL indicate less functional
Mean ADAS-cog, ADCS-ADL and CDR-SB values for the 15 mg group were not statistically significantly different from the placebo group.
Axovant's completer analysis reinforces the protocol-specified analysis of the intent-to-treat (ITT) population from this same study, published in Alzheimer's & Dementia, where patients receiving 35 mg RVT-101 plus donepezil also demonstrated statistically significant improvements on the ADAS-cog and ADCS-ADL compared to patients receiving donepezil alone.
In the 24-week trial, the mean difference in ADCS-ADL scores between those on both drugs and those on donepezil alone was 1.
However, compared with those on placebo, those taking 1,600 mg/day had significant slowing of decline in all three outcome measures: 44% less decline on the ADCS-ADL, 38% less decline on the CDR, and 61% less decline on the ADAS-cog.
Primary study endpoints were changes on two well-established tests of cognition and daily functioning - the ADAS-Cog and ADCS-ADL.
In the 24-week trial, which has not yet been published, the mean difference in ADCS-ADL scores between those on both drugs and those on donepezil alone was 1.
First, the participating raters are extensively trained to administer with the same standardized approach the key rating scales used in Alzheimer's studies, including the ADAS-Cog, ADCS-ADL, MMSE, CDR, and ADCS-CGIC.
During the study, the ADCS-ADL was assessed at the beginning of the study and at weeks 12, 26, 39 and 52.
The primary efficacy endpoint was the ADAS-cog and the secondary efficacy endpoints were the CIBIC-plus, the MMSE, the ADCS-ADL and the NPI.
On the ADCS-ADL measure, the two groups experienced a comparable decline.